Clinical Trials - August 8, 2017
Positive results from Moberg Pharma trial
Moberg Pharma reports positive clinical data for Kerasal Nail/ Emtrix showing that it produces a visible improvement after just one week for nails affected by onychomycosis and/or nail psoriasis. The early effects of treatment with Kerasal Nail/ Emtrix (K101-03) on nails affected by onychomycosis and/or nail psoriasis were investigated in an open-label, multicenter clinical trial of […]
Pharma Business - April 26, 2017
Moberg Pharma extends retail presence
Moberg Pharma expands retail presence for a second Dermoplast product in 7 500 CVS stores and 3 500 Walmart stores. Dermoplast was acquired from Prestige Brands, Inc. in December 2016, contributing to sales and profitability as of January 2017. There are two products under the Dermoplast brand and the additional distribution means that both products are […]
Pharma Business - February 17, 2017
Moberg Pharma’s CEO divests shares
Moberg Pharma announces that Peter Wolpert, founder and CEO of Moberg Pharma, has divested 164,601 shares in Moberg Pharma. Following the divestment, Peter Wolpert holds 435,399 shares, remaining one of the ten largest shareholders in the company. Furthermore, he holds stock options entitling him to subscribe for another 125,000 shares. “The divestment is made for […]
Pharma Business - January 18, 2017
Moberg Pharma expands new skin retail presence
Moberg Pharma announced that their New Skin Spray SKU will be sold in 3 900 Walmart stores and in over 1 500 Walgreens stores. Opening orders expected to ship in mid-March. New Skin was aquired from Prestige Brands. In July 2016. New Skin is the #1 OTC liquid bandage brand in the U.S. It is […]
Pharma Business - November 25, 2016
Moberg Pharma divests PediaCare
Moberg Pharma AB has entered into an agreement with Strides Pharma Inc. to divest the brand PediaCare for a total consideration of $5 million plus the inventory value at closing. Moberg Pharma’s strategy is to build value through profitable growth of strategic brands, to increase the value of pipeline assets and to make value-adding acquisitions. […]
Clinical Trials - September 30, 2016
Moberg Pharma begins patient enrollment
Moberg Pharma has announced that patient enrollment has started in U.S., Canada and Germany in the Phase 3 program investigating MOB-015 for the treatment of onychomycosis. MOB-015 is being evaluated over 52 weeks in two randomized, multicenter, controlled Phase 3 studies. The primary endpoint in both studies is the proportion of patients achieving complete cure […]
